‘Not Yet But Shortly’: EU Remdesivir Filing

 
• By Neena Brizmohun

The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.

Medication prepared for people affected by Covid-19, Remdesivir is a selective antiviral prophylactic against virus that is already in experimental use, conceptual image
Gilead is expected to file an EU marketing application for remdesivir soon • Source: Shutterstock

More from Product Reviews

More from Pink Sheet